Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
SEK 1.48
(0.68%)
SEK 1.48
(0.68%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 4.03 Million SEK | 30.3% |
| 2022 | 3.09 Million SEK | 37.54% |
| 2021 | 2.25 Million SEK | 74.23% |
| 2020 | 1.29 Million SEK | 69.33% |
| 2019 | 763 Thousand SEK | 26.12% |
| 2018 | 605 Thousand SEK | 1505.75% |
| 2017 | 37.67 Thousand SEK | -0.85% |
| 2016 | 38 Thousand SEK | 3799900.0% |
| 2015 | 1.00 SEK | 100.0% |
| 2014 | -32.75 Thousand SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 3.68 Million SEK | -8.81% |
| 2024 Q1 | 4.04 Million SEK | 0.17% |
| 2023 Q2 | 3.15 Million SEK | -0.88% |
| 2023 FY | 4.03 Million SEK | 30.3% |
| 2023 Q4 | 4.03 Million SEK | 4.92% |
| 2023 Q1 | 3.18 Million SEK | 2.75% |
| 2023 Q3 | 3.84 Million SEK | 21.95% |
| 2022 Q1 | 2.77 Million SEK | 23.37% |
| 2022 FY | 3.09 Million SEK | 37.54% |
| 2022 Q3 | 3.31 Million SEK | 8.97% |
| 2022 Q4 | 3.09 Million SEK | -6.66% |
| 2022 Q2 | 3.04 Million SEK | 9.61% |
| 2021 Q3 | 1.39 Million SEK | 4.79% |
| 2021 FY | 2.25 Million SEK | 74.23% |
| 2021 Q2 | 1.33 Million SEK | -2.63% |
| 2021 Q4 | 2.25 Million SEK | 60.9% |
| 2021 Q1 | 1.37 Million SEK | 6.11% |
| 2020 Q3 | 1.05 Million SEK | 15.11% |
| 2020 Q1 | 904 Thousand SEK | 18.48% |
| 2020 FY | 1.29 Million SEK | 69.33% |
| 2020 Q2 | 920 Thousand SEK | 1.77% |
| 2020 Q4 | 1.29 Million SEK | 22.0% |
| 2019 Q4 | 763 Thousand SEK | 0.93% |
| 2019 FY | 763 Thousand SEK | 26.12% |
| 2019 Q3 | 756 Thousand SEK | 14.89% |
| 2019 Q2 | 658 Thousand SEK | 1.23% |
| 2019 Q1 | 650 Thousand SEK | 7.44% |
| 2018 FY | 605 Thousand SEK | 1505.75% |
| 2018 Q2 | 126.46 Thousand SEK | 235.66% |
| 2018 Q1 | 37.67 Thousand SEK | 0.0% |
| 2018 Q3 | 342.2 Thousand SEK | 170.59% |
| 2018 Q4 | 605 Thousand SEK | 76.79% |
| 2017 Q2 | 38 Thousand SEK | 261.9% |
| 2017 FY | 37.67 Thousand SEK | -0.85% |
| 2017 Q1 | 10.5 Thousand SEK | -80.62% |
| 2017 Q3 | 24.75 Thousand SEK | -34.87% |
| 2016 Q4 | 54.18 Thousand SEK | 0.0% |
| 2016 FY | 38 Thousand SEK | 3799900.0% |
| 2016 Q2 | 1.00 SEK | 0.0% |
| 2015 FY | 1.00 SEK | 100.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 FY | -32.75 Thousand SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | -201699900.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 196.3% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 156.53% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 72.935% |
| Intervacc AB (publ) | 10.48 Million SEK | 61.519% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | 161460.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 88.549% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 55.514% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 206971.795% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | -28.063% |
| Saniona AB (publ) | 1.00 SEK | -403399900.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 348.093% |
| Biovica International AB (publ) | 2.19 Million SEK | -83.447% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -403399900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | -93.942% |
| Xintela AB (publ) | 398 Thousand SEK | -913.568% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -476.286% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 567.44% |
| Amniotics AB (publ) | 534 Thousand SEK | -655.431% |
| 2cureX AB (publ) | -1000.00 SEK | 403500.0% |
| CombiGene AB (publ) | -1.79 Million SEK | 324.236% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 80.253% |
| Camurus AB (publ) | 100.95 Million SEK | 96.004% |
| Corline Biomedical AB | -3.85 Million SEK | 204.589% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -403300.0% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | 4.28 Million SEK | 5.748% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 58.803% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 181.842% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | -639.862% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 90.786% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 1002.489% |
| Nanologica AB (publ) | 2.97 Million SEK | -35.688% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 1356.13% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 65.941% |
| Alzinova AB (publ) | -3.27 Million SEK | 223.063% |
| Oncopeptides AB (publ) | 2.42 Million SEK | -66.351% |
| Pila Pharma AB (publ) | 1.00 SEK | -403399900.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 271567.026% |
| Simris Alg AB (publ) | 1.09 Million SEK | -269.753% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 83.227% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 96.225% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -292.412% |